Event Date/Time: May 06, 2002 End Date/Time: May 07, 2002
Report as Spam

Description

ORGANIZED INTO THREE SECTIONS:

- DISCOVERY & DRUG TARGET IDENTIFICATION
- LEAD STRUCTURE IDENTIFICATION & CHARACTERIZATION
- PRE-CLINICAL/CLINICAL DEVELOPMENT


HIGHLIGHTS INCLUDE:

Signaling Mechanism that Regulate Expression of UCP1
Sheila Collins, Ph.D., Duke University Medical Center

Elucidation of Signaling Pathways and Transcription
Stephen R. Farmer, M.D., Boston University School of Medicine

Leptin as a Human Therapeutic
Alex DePaoli, M.D., Amgen

Inhibitors at New Allosteric Sites for Glycogen Phosphorylase & Fructose-1,6-Bisphosphatase
Judith L. Treadway, Ph.D., Pfizer Global R & D - Groton Laboratories


FEATURING:

- Type 2 Diabetes Insulin Sensitizer
- Leptin
- Next Generation Diabetes Drug Targets
- Thermogenesis
- Antidiabetic Properties of GSK3 Inhibitors
- PPAR-Gamma
- Antisense Use in Diabetes
- Transcription Factors
- Insulin Resistance
- Combination Therapy in Obesity
- Mitochodrial Approaches
- Functional Genomics

Venue

Types